To be rescheduled: City-Wide Medical Grand Rounds: Neuroprotection therapies for Parkinson's disease: "One drug does not fit all"
The health, safety and well-being of our community members is very important to us. We regret to inform you that owing to the current situation with COVID-19, City-Wide Medical Grand Rounds have been cancelled until further notice.
This presentation will be rescheduled.
Neuroprotection therapies for Parkinson's disease: “One drug does not fit all”
Anthony E. Lang, OC, FRCPC, FAAN, FCAHS, FRSC
Director, Edmond J. Safra Program in Parkinson’s Disease, the Morton and Gloria Shulman Movement Disorders Clinic and the Rossy Progressive Supranuclear Palsy Centre, Toronto Western Hospital, University Health Network and the University of Toronto
Lily Safra Chair in Movement Disorders, University Health Network
Jack Clark Chair for Parkinson’s Disease Research, University of Toronto
Senior Scientist, Krembil Brain Institute, University Health Network
Principle Investigator, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto
At the end of the presentation, participants should be able to:
- Explain the basis for considering one drug vs combination therapy in disease modification for Parkinson’s disease,
- Recognize the broad heterogeneity of Parkinson’s disease and explain possible reasons for this,
- Explain the various different proposed mechanisms underlying Parkinson’s disease pathogenesis,
- Debate reasons for thinking that Parkinson’s disease represents a single vs multiple diseases, and
- Propose reasons for considering the use of multiple drugs in disease modification and how these might be studied with respect to drug development and clinical trials.